Relevance of mango use in patients with 2 type diabetes mellitus

Samuel Oyejide, V.S. Potaskalova, M.V. Khaitovych
Bogomolets national medical university, Kiev

Mangiferin has a therapeutic potential against lifestyle disorders. Mangiferin (2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one) can be isolated from higher plants, as well as from the mango tree containing tannins called anthocyanidins, which help treat early diabetes. The leaves contain the compound 3-beta-taraxerol and ethyl acetate extract, which interacts with insulin, activating GLUT4 and stimulating glycogen synthesis. Mango leaves have powerful antioxidant properties because they contain a large amount of flavonoids, phenols, zeaxanthin and beta-carotene. Animal studies have shown that mangiferin can counteract the free radical associated with cancer, diabetes, and other diseases.

Keywords: Diabetes mellitus, Mangifera indica, flavonoids, treatment.
Mangiferin is obtained from mango with many other active ingredients, but with poor lipophilicity and hydrophilicity. Mangiferin concentrations were measured by High performance liquid chromatography (RP-HPLC) in rats administered orally with crude mangiferin and the mangiferin-phospholipid complex. The results showed that the solubility of the mangiferin-phospholipid complex in water and n-octanol was improved, and the oil-water complex distribution coefficient improved 6.2 times. In addition, rats showed a significant improvement in intestinal permeability. AUC and peak plasma concentration in rats treated with untreated mangiferin were lower than those treated with mangiferin-phospholipid complex. In the experiment, when the mangiferin complex was administered to rats that received carbon tetrachloride, hepatoprotective property was revealed by restoring hepatic antioxidants and serum hepatic enzymes [11, 15, 16].

The bioavailability of mangiferin in rats increased by 9.75 times when using the mangiferin complex compared to pure mangiferin. In addition, hepatoprotection in rats was increased by administration of the mangiferin-soy phospholipid complex due to improved bioavailability. Zhang et al. It was determined that the recovery of mangiferin in the eye ranged from 80.0 to 85.6%, and in plasma from 82.0 to 88.0% [8]. Mangiferin can pass through the blood-brain barrier and it is proved that it is effective in reducing the treatment time for various eye diseases. Similarly, the concentration of mangiferin in plasma (from 0.6 to 24 μg/ml) and urine (from 0.48 to 24 μg/ml) was studied using HPLC [9].

Eight weeks of mangiferin treatment significantly lowered plasma glucose and triglyceride (TG) levels in db/db mice. It enhanced pancreatic β-cell mass and amount of glucose and insulin uptake along with increased the phosphorylation of AMP-activated protein kinase (AMPK) in n 3 T3-L1 cells. It also activated the AMP-activated protein kinase (AMPK) phosphorylation of AMPK and activated along its downstream target, acetyl-CoA carboxylase (ACC) in the liver, hypothalamus, muscle and adipose tissue of C57BL/6 mice. Likewise, the oral administration of mangiferin (20 mg/kg, intraperitoneal administration (i.p.)) for 4 weeks in streptozotocin-induced hyperglycemic rats improved insulin sensitivity, modulated lipid profile, and reverted adipokine levels. Similarly, different concentrations of mangiferin (15, 30, and 60 mg/kg/day oral administration) were given to diabetic rats for 9 weeks, resulting in a reduction of osteopontin production, kidney inflammation, and renal fibrosis. Chronic treatment with mangiferin prevented renal glomeruli fibrosis, as well as decreased α-smooth muscle actin and collagen IV expression in the diabetic rat. In contrast, this also reduced the expression of osteopontin in the renal-cortex of diabetic rats, COX-2 and NF-κB P65 subunits. Finally, mangiferin reduced interleukin-1β in the serum and kidneys of diabetic rats [12].

Mangiferin has also been shown to lower ROS production and decrease intracellular antioxidant defenses, and mediates diabetic nephropathy, as it modulates the MAPK (P38, JNK and ERK1/2), PKC isoforms (PKCa, PKCβ and PKCε), TGF-β1 pathways, as well as the NF-κB signaling cascades involved in this pathophysiology Wang et al. determined that mangiferin exhibited an antidiabetic role in adult C57BL/6 J mice. The administration of mangiferin (30 and 90 mg/kg BW) improved glucose tolerance and glycemia, increased β-cell hyperplasia and serum insulin levels, lowered β-cell apoptosis, elevated β-cell proliferation and upregulated cyclin D1, D2 and cyclin-dependent kinase 4 (Cdk4) at 7–14 days post-partum. Additionally, mangiferin promoted β-cell regeneration and the expression of pancreatic and duodenal homeobox gene 1 (PDX-1), glucose transporter 2 (GLUT-2), neurogenin 3 (Ngn3), glucokinase (GCK), and Forkhead box protein O1 (Foxo-1) [2].

Mangiferin (15, 30, and 60 mg/kg) treatment for nine weeks significantly improved chronic renal insufficiency of diabetic rats, and was demonstrated to reduce kidney weight index, albuminuria, glomerular extracellular matrix expansion, blood urea nitrogen, and glomerular and accumulation basement membrane thickness. Meanwhile, it also enhanced the enzymatic activity, as well as the protein and mRNA expression of Glo-1, as well as decreased the mRNA and protein expression of advanced glycation endproducts (AGEs) and receptor for advanced glycation end products (RAGE) receptor in diabetic rat renal cortex. Moreover, it also reduced the concentrations of malondialdehyde (MDA) and enhanced the concentrations of glutathione in the diabetic rat kidney [18].

Mangiferin (10 and 20 mg/kg) administered once daily for 28 days in STZ-induced diabetic rats exhibited anti-diabetic activity. It significantly reduced plasma low-density lipoprotein cholesterol (LDL-C) and TG levels, lowered total cholesterol level and increased high-density HDL-C levels. Furthermore, the atherogenic index of diabetic rats decreased and mangiferin improved oral-glucose tolerance in normal rats loaded with glucose [7].

In diabetic nephropathy rats, mangiferin considerably lowered the serum levels of advanced glycation end products, red blood cell sorbitol concentrations, malonaldehyde level, 24 h albuminuria excretion, and enhanced serum antioxidant enzymes

| Health perspectives of Mangiferin in the treatment of diabetes mellitus 2 |
|---------------------------------------------------------------|
| **Diabetes prevention**                                        |
| Increased glucose and pancreatic beta cell mass               |
| Activation of phosphorylation of AMP-activated protein kinase  |
| Increasing insulin sensitivity, correcting the lipid profile and normalizing adipokine levels |
| TGF-β1 pathways, PKC isoforms (PKCa, PKCβ and PKCε), MAPK (P38, JNK and ERK1/2) modulated |
| β-cell apoptosis reduction                                    |
| Activate cyclin D1, cyclin D2 and Cdk4 (cyclin-dependent kinase 4), which promotes β-cell regeneration and expression of the duodenal and pancreatic homeobox gene 1 (PDX-1), glucose transporter 2 (GLUT-2), neurogenin 3 (Ngn3), glucokinase (GCK) and Forkhead box protein O1 (Foxo-1) |
| The expression of Glo-1 mRNA is enhanced, the activity of protein and enzymes is increased |
| Decreased expression of mRNA and protein receptors in glycation end products and in glyclosylation end products |
| Reducing the concentration of red blood cells, sorbitol, the level of malonaldehyde |
| Inhibition of expansion of the glomerular extracellular matrix, accumulation and transformation of overexpression of growth factor beta 1 |
| Prevention of renal glomerular fibrosis                        |
| Decreased expression of alpha smooth muscle of collagen IV and actin |
| Decreased expression of COX-2, NF-κB P65 and osteopontin subunit |
| Decrease in interleukin-1β                                      |
such as superoxide dismutase and glutathione peroxidase. In addition, it inhibits the expansion of glomerular extracellular-matrix and diabetic nephropathy rat glomeruli TGF-β1 accumulation and transformation, high glucose-induced mesangial cell proliferation and mesangial cells collagen IV in a glomerular diabetic nephropathy rat model [12].

Mangifera indica leaf extract induce production of Adiponectin in the adipose tissue and leptin production both in adipose tissue and small intestine. This increases the glucose uptake in the muscle and liver. Adiponectin and leptin increase improve the action of Glut-4 in liver and muscles. It improves glucose metabolism and adipogenesis [6].

Adiponectin prevents insulin resistance, it exerts insulin-sensitizing effect through binding to its receptors, leading to activation of AMPK, PPAR-α, and potentially other unknown molecular pathways. In obesity-linked insulin resistance, both adiponectin and adiponectin receptors are downregulated, leading to activation of a signaling pathways involved in metabolism regulation. Up-regulation of adiponectin/adiponectin receptors or enhancing adiponectin receptor function may be an interesting therapeutic strategy for obesity-linked insulin resistance and diabetes mellitus type 2 [14, 19].

The health perspectives of Mangiferin indica in treatment of diabetes mellitus 2 is shown in Table.

REFERENCES
1. Analogue and antioxidant activity of mangiferin and its derivatives: the structure activity relationship / Dar A, Faizi S, Naqui S, et all. // Biol Pharm Bull. – 2005. – № 28 (4). – Р. 596–600.
2. Attie AD. PGC-1alpha at the crossroads of type 2 diabetes / AD. Attie, CM. Kendziorpski // Nat Genet. – 2003. – № 34. – Р. 244–245.
3. Beckman C.H. Phenolic-storing cells: Keys to programmed cell death and peroxidation in will disease resistance and in general defence responses in plants? / C.H. Beckman // Physiol. Mol. Plant. Pathol. – 2000. – № 57. – Р. 101–110. doi: 10.1006/ppmp.2000.0287
4. Burton-Freeman B.M. Mangos and their bioactive components: Adding variety to the fruit plate for health / B.M. Burton-Freeman, A.K. Sandhu, I. Edrisinge // Food Funct. – 2017. – № 8. – Р. 3010–3032. doi: 10.1039/C7FO00190H
5. Civitarese AE. Mitochondrial energetics and insulin resistance / Civitarese AE., Ravussin E. // Endocrinology. – 2008. – № 149. – Р. 950–954.
6. Decline in skeletal muscle mitochondrial function with aging in humans / KR. Short, ML. Bigelow, J. Kahl, et all. // Proc Natl Acad Sci USA. – 2005. – № 102. – Р. 5616–5623.
7. Effect of mangiferin on hyperglycemia and atherogenecity in STZ diabetic rats / Muruganandan Sharmugam, Krishnamorthy Srinivasan, S Gupta et all. // Journal of Ethnopharmacology. – 2005. – № 97 (3). – Р. 497–501. DOI: 10.1016/j.jep.2004.12.010.
8. Hydroxytyrosol supplementation ameliorates the metabolic disturbances in white adipose tissue from mice fed a high-fat diet through recovery of transcription factors Nr2, SREBP-1c, PPAR-gamma and NF-kappaB / P. Illesca, R. Valenzuela, A. Espinosa, et all. // Biomed. Pharm. – 2019. – № 149. – Р. 2472–2481. doi: 10.1016/j.jep.2004.12.010.
9. Jagetia GC. Effect of mangiferin on radiation-induced micronucleus formation in cultured human peripheral blood lymphocytes / GC. Jagetia, VA. Venkatesha // Environ Mol Mutagen. – 2005. – № 46 (1). – Р. 12–21.
10. Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunctions: an overview / J. Liu // Neurochem Res. – 2008. – № 33. – Р. 194–203.
11. Mangiferin: A bioactive xanthohiod, not only from mango and not just antioxidant / A. Matkowsky, P. Kuś, E. Góralczyk, et all. // Mini Rev Med Chem. – 2013. – № 13 (3). – Р. 439–455.
12. Mangiferin: a natural miracle bioactive compound against lifestyle related disorders / M. Imran, M.S. Arshad, M.S. Butt // Lipids Health Dis. – 2017. – № 16. – Р. 84. doi: 10.1186/s12944-017-0449-y.
13. Muruganandan S. Immunotherapeutic effects of mangiferin mediated by the inhibition of oxidative stress to activated lymphocytes, neutrophils and macrophages / S. Muruganandan, J. Lai, PK. Gupta. // Toxicology. – 2005. – № 215 (1–2). – Р. 57–68.
14. Nair KS. Aging muscle / KS. Nair et all. // Am J Clin Nutr. – 2005. – № 81. – Р. 355–364. DOI: 10.1093/ajcn/81.1.215S.
15. Up-regulation of glyoxalase 1 by mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats / Yao-Wu L., Xia Zhu, Liang Zhang // European Journal of Pharmacology. – 2013. – № 721(1-3). – Р. 355–364. DOI: 10.1016/j.ejphar.2013.08.029
16. Protective effects of Mangifera indica leaf extract, mangiferin and selected antioxidants against TPA-induced biomolecules oxidation and peritoneal macrophage activation in mice / GM Sánchez, L Re, A. Giuliani, et all. // Pharmacol Res. – 2000. – № 42 (6). – Р. 565–73.
17. Scalbert A. Antioxidants and beyond / A. Scalbert, I.T. Johnson, M. Saltmarsh // Am. J. Clin. Nutr. – 2005. – № 81. – Р. 215–217. doi: 10.1093/ajcn/81.1.215S.
18. Protective effects of Mangifera indica leaf extract, mangiferin and selected antioxidants against TPA-induced biomolecules oxidation and peritoneal macrophage activation in mice / GM Sánchez, L Re, A. Giuliani, et all. // Pharmacol Res. – 2000. – № 42 (6). – Р. 565–73.
19. Wang YC. Forecasting the obesity epidemic in the aging U.S. population / YC Wang, GA Colditz, KM Kunz // Obesity (Silver Spring). – 2007. – № 15. – Р. 2855–2865.